Managing Partner, PGx Consulting, LLC
An attorney by training, Mollie Roth is the Managing Partner of PGx Consulting, which she started in 2010 to provide customized, personalized medicine specific business services to growing life sciences and biotech companies. Mollie has almost a decade of experience helping companies understand and overcome the hurdles associated with the variety of issues that fall within the personalized medicine umbrella, in a variety of contexts - including legal, strategic development, business and corporate development as well as marketing and operations.
Prior to the launch of PGx, Mollie was Chief Operating Officer for Diaceutics, where she was responsible for day-to-day operations as well as overseeing the strategic development and execution of the company’s corporate and product plans, created a strategic marketing and communications plan, directed the strategic and operational leadership of business development and sales efforts as well as leading the company’s thought leadership in the personalized medicine space.
Prior to 2007, Mollie was an attorney in private practice focused on patent and product liability litigation on behalf of the pharmaceutical industry for Kaye Scholer in New York, New York and Nixon Peabody in Washington, DC. While at Nixon Peabody, Mollie created a specialization in pharmacogenomics, speaking to members of the pharmaceutical and venture capital industries on risk management issues relating to potential litigation liabilities in the personalized medicine space.
Mollie holds a B.A. in neuropsych from Rutgers University and a J.D. from Vermont Law School, and anticipates presently completing her L.LM in Biotechnology and Genomics from the Sandra Day O’Connor College of Law at Arizona State University. Mollie also served as a Visiting Faculty Fellow in the law school’s Center for the Study of Law, Science, & Technology focused on research relating to the intersection of law and personalized medicine as well as teaching several related courses. She currently sits on the Board of the Center for Law, Science and Innovation.